The efficacy of first-line combination therapy with everolimus plus lanreotide for gastroenteropancreatic neuroendocrine tumour with a poor prognostic factor: Updated and subgroup analysis of the phase III study, STARTER-NET (JCOG1901)

#4670

Introduction: Everolimus monotherapy provided a limited median progression-free survival (PFS) for gastroenteropancreatic neuroendocrine tumours (GEP-NETs), there remains a necessity for better therapeutic approaches.

Aim(s): This randomised phase III trial was conducted to evaluate the efficacy of everolimus plus lanreotide (EVE/LAN) in patients with advanced grade 1 (G1) and G2 GEP-NETs with poor prognostic factors (PPFs) in the first-line setting.

Materials and methods: Patients with G1 or G2, non-functioning GEP-NETs with PPFs [Ki-67 labelling index (LI) 5-20% or diffuse liver metastases] were randomly assigned to EVE (10 mg/day) or EVE/LAN (EVE + LAN 120 mg every 28 days). The primary endpoint and key secondary endpoint were PFS and overall survival (OS).

Conference:

Presenting Author:

Authors: Hijioka S, Honma Y, Machida N, Mizuno N, Hamaguchi T,

Keywords: everolimus, lanreotide, PFS, RCT,